Axsome Therapeutics (AXSM) announced that it has reached agreement with Sandoz (SDZNY) to dismiss the patent litigation related to Axsome’s product Sunosi. The litigation, which was pending in the United States District Court for the District of New Jersey, resulted from submission by Sandoz of an Abbreviated New Drug Application, ANDA, to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of Sunosi in the United States. Sandoz withdrew its ANDA for a generic equivalent of Sunosi, and, as a result, the litigation has been dismissed without prejudice.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Biotech Alert: Searches spiking for these stocks today
- Axsome Therapeutics price target lowered to $130 from $131 at RBC Capital
- 3 Best Stocks to Buy Now, 8/6/2024, According to Top Analysts
- Axsome Therapeutics upgraded to Buy at BofA ahead of ADA data
- Axsome Therapeutics price target lowered to $180 from $190 at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com